Etoposide for epidemic Kaposi's sarcoma: A phase II study

Piet J.M. Bakker; Sven A. Danner; Joep M.A. Lange; Kees H.N. Veenhof

doi:https://doi.org/10.1016/0277-5379(88)90157-5

Etoposide for epidemic Kaposi's sarcoma: A phase II study

Piet J.M. Bakker, Sven A. Danner, Joep M.A. Lange, Kees H.N. Veenhof

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

Abstract

Fourteen untreated patients with epidemic Kaposi's sarcoma stages III and IV were treated with etoposide 150 mg/m² on 3 consecutive days every 4 weeks. No responses were observed. Myelosuppression was severe with white blood count WHO grade 3-4 in nine patients and with platelets WHO grade 3-4 in one patient. Three patients developed opportunistic infections during therapy. It is concluded that etoposide is inactive in epidemic Kaposi's sarcoma.

Original language	English
Pages (from-to)	1047-1048
Number of pages	2
Journal	European Journal of Cancer and Clinical Oncology
Volume	24
Issue number	6
DOIs	https://doi.org/10.1016/0277-5379(88)90157-5
Publication status	Published - Jun 1988

Access to Document

https://doi.org/10.1016/0277-5379(88)90157-5

Cite this

@article{d0dd31541269423781a3e40320a0df73,

title = "Etoposide for epidemic Kaposi's sarcoma: A phase II study",

abstract = "Fourteen untreated patients with epidemic Kaposi's sarcoma stages III and IV were treated with etoposide 150 mg/m2 on 3 consecutive days every 4 weeks. No responses were observed. Myelosuppression was severe with white blood count WHO grade 3-4 in nine patients and with platelets WHO grade 3-4 in one patient. Three patients developed opportunistic infections during therapy. It is concluded that etoposide is inactive in epidemic Kaposi's sarcoma.",

author = "Bakker, {Piet J.M.} and Danner, {Sven A.} and Lange, {Joep M.A.} and Veenhof, {Kees H.N.}",

year = "1988",

month = jun,

doi = "https://doi.org/10.1016/0277-5379(88)90157-5",

language = "English",

volume = "24",

pages = "1047--1048",

journal = "European Journal of Cancer and Clinical Oncology",

issn = "0277-5379",

publisher = "Pergamon Press",

number = "6",

}

TY - JOUR

T1 - Etoposide for epidemic Kaposi's sarcoma

T2 - A phase II study

AU - Bakker, Piet J.M.

AU - Danner, Sven A.

AU - Lange, Joep M.A.

AU - Veenhof, Kees H.N.

PY - 1988/6

Y1 - 1988/6

N2 - Fourteen untreated patients with epidemic Kaposi's sarcoma stages III and IV were treated with etoposide 150 mg/m2 on 3 consecutive days every 4 weeks. No responses were observed. Myelosuppression was severe with white blood count WHO grade 3-4 in nine patients and with platelets WHO grade 3-4 in one patient. Three patients developed opportunistic infections during therapy. It is concluded that etoposide is inactive in epidemic Kaposi's sarcoma.

AB - Fourteen untreated patients with epidemic Kaposi's sarcoma stages III and IV were treated with etoposide 150 mg/m2 on 3 consecutive days every 4 weeks. No responses were observed. Myelosuppression was severe with white blood count WHO grade 3-4 in nine patients and with platelets WHO grade 3-4 in one patient. Three patients developed opportunistic infections during therapy. It is concluded that etoposide is inactive in epidemic Kaposi's sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0023920014&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/0277-5379(88)90157-5

DO - https://doi.org/10.1016/0277-5379(88)90157-5

M3 - Article

C2 - 3409942

SN - 0277-5379

VL - 24

SP - 1047

EP - 1048

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

IS - 6

ER -

Etoposide for epidemic Kaposi's sarcoma: A phase II study

Abstract

Access to Document

Other files and links

Cite this